RecruitingPhase 1NCT06579144

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

Studying Hemophilia A

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Swedish Orphan Biovitrum
Principal Investigator
Elena Santagostino, MD
Sobi AB
Intervention
Efanesoctocog alfa(drug)
Enrollment
24 enrolled
Eligibility
18-65 years · MALE
Timeline
20252026

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06579144 on ClinicalTrials.gov

Other trials for Hemophilia A

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia A

← Back to all trials